LeMaitre Vascular (LMAT) Competitors $79.91 -10.33 (-11.45%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LMAT vs. STVN, GKOS, NARI, INSP, BLCO, SLNO, IRTC, TMDX, PRCT, and NVSTShould you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), TransMedics Group (TMDX), PROCEPT BioRobotics (PRCT), and Envista (NVST). These companies are all part of the "medical equipment" industry. LeMaitre Vascular vs. Stevanato Group Glaukos Inari Medical Inspire Medical Systems Bausch + Lomb Soleno Therapeutics iRhythm Technologies TransMedics Group PROCEPT BioRobotics Envista Stevanato Group (NYSE:STVN) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Is STVN or LMAT a better dividend stock? Stevanato Group pays an annual dividend of €0.06 per share and has a dividend yield of 0.3%. LeMaitre Vascular pays an annual dividend of $0.80 per share and has a dividend yield of 0.9%. Stevanato Group pays out 12.5% of its earnings in the form of a dividend. LeMaitre Vascular pays out 41.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. LeMaitre Vascular has increased its dividend for 14 consecutive years. LeMaitre Vascular is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Does the MarketBeat Community favor STVN or LMAT? LeMaitre Vascular received 484 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 70.45% of users gave LeMaitre Vascular an outperform vote while only 63.27% of users gave Stevanato Group an outperform vote. CompanyUnderperformOutperformStevanato GroupOutperform Votes3163.27% Underperform Votes1836.73% LeMaitre VascularOutperform Votes51570.45% Underperform Votes21629.55% Do institutionals & insiders have more ownership in STVN or LMAT? 84.6% of LeMaitre Vascular shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 10.8% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, STVN or LMAT? Stevanato Group has higher revenue and earnings than LeMaitre Vascular. Stevanato Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStevanato Group$1.10B5.69$157.62M$0.4843.21LeMaitre Vascular$219.86M9.27$30.10M$1.9446.52 Do analysts prefer STVN or LMAT? LeMaitre Vascular has a consensus target price of $98.14, indicating a potential upside of 8.76%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86LeMaitre Vascular 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.63 Does the media refer more to STVN or LMAT? In the previous week, LeMaitre Vascular had 13 more articles in the media than Stevanato Group. MarketBeat recorded 17 mentions for LeMaitre Vascular and 4 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.35 beat LeMaitre Vascular's score of 0.49 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 6 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, STVN or LMAT? Stevanato Group has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Is STVN or LMAT more profitable? LeMaitre Vascular has a net margin of 19.40% compared to Stevanato Group's net margin of 10.47%. LeMaitre Vascular's return on equity of 13.15% beat Stevanato Group's return on equity.Company Net Margins Return on Equity Return on Assets Stevanato Group10.47% 9.86% 5.79% LeMaitre Vascular 19.40%13.15%11.47% SummaryLeMaitre Vascular beats Stevanato Group on 15 of the 21 factors compared between the two stocks. Get LeMaitre Vascular News Delivered to You Automatically Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LMAT vs. The Competition Export to ExcelMetricLeMaitre VascularSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.04B$4.33B$5.54B$7.93BDividend Yield0.87%39.93%5.09%4.23%P/E Ratio49.3130.0322.5818.55Price / Sales9.2755.31401.13103.29Price / Cash56.5251.0838.1834.62Price / Book6.746.056.774.25Net Income$30.10M$68.71M$3.22B$248.18M7 Day Performance-1.50%-0.24%1.10%0.91%1 Month Performance4.18%-2.90%2.49%2.59%1 Year Performance35.15%21.00%15.76%4.02% LeMaitre Vascular Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LMATLeMaitre Vascular2.7507 of 5 stars$79.91-11.4%$98.14+22.8%+35.1%$1.80B$219.86M43.57490Earnings ReportNews CoverageGap DownSTVNStevanato Group1.1556 of 5 stars€21.65-1.0%N/A-26.5%$6.56B$1.10B46.064,650Positive NewsGKOSGlaukos4.7544 of 5 stars$88.17-2.3%$156.17+77.1%-15.8%$4.99B$383.48M-30.72780Earnings ReportAnalyst ForecastNews CoverageNARIInari Medical0.306 of 5 stars$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800News CoverageINSPInspire Medical Systems4.8529 of 5 stars$144.74-3.6%$218.90+51.2%-35.2%$4.31B$802.80M83.67760Upcoming EarningsPositive NewsBLCOBausch + Lomb3.8245 of 5 stars$12.05-0.1%$18.82+56.2%-15.6%$4.26B$4.79B-13.2412,500Earnings ReportAnalyst ForecastNews CoverageSLNOSoleno Therapeutics4.6541 of 5 stars$68.93-1.5%$99.63+44.5%+57.8%$3.16BN/A-20.7630Upcoming EarningsNews CoveragePositive NewsIRTCiRhythm Technologies0.8597 of 5 stars$98.63-2.3%$119.73+21.4%-2.8%$3.10B$591.84M-27.101,790Earnings ReportAnalyst ForecastNews CoverageGap UpTMDXTransMedics Group3.2097 of 5 stars$87.72-0.6%$122.70+39.9%-23.1%$2.97B$441.54M93.32210Analyst ForecastPRCTPROCEPT BioRobotics2.6981 of 5 stars$53.43+0.8%$91.43+71.1%-12.8%$2.93B$224.50M-27.40430Analyst RevisionGap UpHigh Trading VolumeNVSTEnvista3.6531 of 5 stars$14.88-2.0%$19.96+34.2%-17.1%$2.56B$2.51B-2.2912,700Earnings ReportAnalyst ForecastNews Coverage Related Companies and Tools Related Companies STVN Alternatives GKOS Alternatives NARI Alternatives INSP Alternatives BLCO Alternatives SLNO Alternatives IRTC Alternatives TMDX Alternatives PRCT Alternatives NVST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LMAT) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LeMaitre Vascular, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LeMaitre Vascular With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.